Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 25c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $240.79 -2.44%
EPS Growth %: -20.5%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.64, $0.25 better than the analyst estimate of $6.39. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.16 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- Ramp In Talks For New Funding At $60 Billion Valuation - Bloomberg
- OpenAI CFO: enterprise business has been on a tear
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
